Glutathione pathway genes and lung cancer risk in young and old populations

Division of Epidemiology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.
Carcinogenesis (Impact Factor: 5.33). 11/2004; 25(10):1935-44. DOI: 10.1093/carcin/bgh203
Source: PubMed


Multiple enzymes with overlapping functions and shared substrates in the glutathione (GSH) metabolic pathway have been associated with host susceptibility to tobacco smoke carcinogens and in lung cancer etiology. However, few studies have investigated the differing and interacting roles of GSH pathway enzymes with tobacco smoke exposure on lung cancer risk in young (<50 years of age) and old (>80 years of age) populations. Between 1997 and 2001, 237 primary lung cancer patients (170 young, 67 old) and 234 controls (165 young, 69 old) were enrolled at the Mayo Clinic. Using PCR amplification of genomic DNA, polymorphic markers for gammaGCS, GPX1, GSTP1 (I105V and A114V), GSTM1 and GSTT1 were genotyped. Recursive partitioning and logistic regression models were used to build binary classification trees and to estimate odds ratios (OR) and 95% confidence intervals for each splitting factor. For the young age group, cigarette smoking had the greatest association with lung cancer (OR = 3.3). For never smokers, the dividing factors of recursive partitioning were GSTT1 (OR = 1.7), GPX1 (OR = 0.6) and GSTM1 (OR = 4.3). For the old age group, smoking had the greatest association with lung cancer (OR = 3.6). For smokers, the dividing factors were GPX1 (OR = 3.3) and GSTP1 (I105V) (OR = 4.1). Results from logistic regression analyses supported the results from RPART models. GSH pathway genes are associated with lung cancer development in young and old populations through differing interactions with cigarette smoking and family history. Carefully evaluating multiple levels of gene-environment and gene-gene interactions is critical in assessing lung cancer risk.

Download full-text


Available from: Mariza Andrade, Feb 24, 2014
  • Source
    • "Lung cancer generally occurs in people between 50 and 80 years old[11]. However, it has become less rare in patients younger than 45 years over the last decades[12][13]. Median age of our cases was 54 years; this is related to the time that cancer takes to develop after starting to smoke leading to the occurrence of more smoking related carcinoma in the older group. "

    Full-text · Article · Sep 2015 · Advances in Lung Cancer
  • Source
    • "For gene modules that are upregulated in only NSCLC, some are enriched with function involved in DNA replication, which is consistent with previous findings that genes DNA repair are closely related to the risk of NSCLC [27]. For gene modules downregulated only in NSCLC, some of them are enriched with Notch pathway and glutathione transferase activity, both of which have been reported to be strongly related to lung cancer [28] [29]. Thus, functional analysis of differentially expressed genes supports that these gene modules are strongly related to lung cancer development, making it possible for us to conduct further exploitation to identify gene biomarkers that can be of diagnosis use for distinguishing the two subtypes of lung cancer. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lung cancer consists of two main subtypes: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) that are classified according to their physiological phenotypes. In this study, we have developed a network-based approach to identify molecular biomarkers that can distinguish SCLC from NSCLC. By identifying positive and negative coexpression gene pairs in normal lung tissues, SCLC, or NSCLC samples and using functional association information from the STRING network, we first construct a lung cancer-specific gene association network. From the network, we obtain gene modules in which genes are highly functionally associated with each other and are either positively or negatively coexpressed in the three conditions. Then, we identify gene modules that not only are differentially expressed between cancer and normal samples, but also show distinctive expression patterns between SCLC and NSCLC. Finally, we select genes inside those modules with discriminating coexpression patterns between the two lung cancer subtypes and predict them as candidate biomarkers that are of diagnostic use.
    Full-text · Article · Aug 2015
  • Source
    • "Four studies have looked at the association between the Pro198Leu polymorphism and the risk of lung cancer [24] [32] [33] [46]. Compared to Pro homozygotes, two studies – in Finland and Korea – found a significantly increased risk of lung cancer in Leu hetero/homozygotes [24] [32], while a small US study found a significantly-increased risk in neversmoker Leu hetero-/homozygotes (only 13 cases), though a significantly-decreased risk was found in elderly smokers [46]. However, in the fourth study, carried out in Denmark, Leu/Leu homozygosity was associated with decreased risk [33]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Knowledge of the plasma selenium levels associated with optimised concentration or activity of specific selenoproteins can provide considerable insights from epidemiological data on the possible involvement of those selenoproteins in health, most notably with respect to cancer. For cohort studies, if selenoproteins such as glutathione peroxidase and selenoprotein P are relevant to cancer, one might only expect to see an effect on risk when the concentrations in the cohort range from below, to above, the level needed to optimise the activity or concentration of these enzymes. Similarly, trials would only show a beneficial effect of supplementation if selenium status were raised from below, to above, the optimal concentration for the selenoproteins likely to be implicated in cancer risk, as occurred in the NPC trial but not in SELECT. The most powerful evidence for the involvement of selenoproteins in human health comes from epidemiological studies that have related single nucleotide polymorphisms in selenoproteins to disease risk. The totality of the evidence currently implicates GPx1, GPx4, SEPS1, Sep15, SEPP1 and TXNRD1 in conditions such as cardiovascular disease, pre-eclampsia and cancer. Future studies therefore need to determine not only selenium status, but genotype, both in selenoproteins and related pathways, when investigating the relationship of selenium with disease risk.
    Preview · Article · Apr 2009 · Biochimica et Biophysica Acta
Show more